Replies to post #240596 on Biotech Values

[DewDiligence]

BIIB/DNLI start phase-3 in Parkinson’s disease with LRRK2 mutations:

https://www.globenewswire.com/news-release/2022/10/03/2526798/0/en/Biogen-and-Denali-Therapeutics-Announce-Initiation-of-the-Phase-3-LIGHTHOUSE-Study-in-Parkinson-s-Disease-Associated-with-LRRK2-Pathogenic-Mutations.html

The primary endpoint of the LIGHTHOUSE study is time to confirmed worsening, as assessed using the Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) over the treatment period, up to 180 weeks. Participants will be randomized to receive oral BIIB122 or placebo once daily.